Robert Lufkin MD: Extracranial Manifestations of Alzheimer's Risk

Alzheimer's disease risk assessment relies on advanced MRI imaging that extends beyond the brain to identify systemic health factors contributing to cognitive decline. Beyond measuring hippocampal atrophy—a critical biomarker detectable up to two decades before symptom onset—these scans evaluate airway anatomy for obstructive sleep apnea, sinus health for chronic or fungal inflammation, and dental status for hidden periodontal disease. Unlike CT or PET scans, MRI technology avoids ionizing radiation, facilitating safe, longitudinal monitoring of brain volume and systemic health. Tracking the velocity of hippocampal change over time provides a more accurate diagnostic tool than static measurements, enabling early, proactive lifestyle interventions. This multifactorial approach shifts the focus from late-stage symptom management to early prevention, offering a tangible, data-driven path to preserve cognitive function and mitigate the devastating personal and financial impacts of dementia.